Related Experiment Video
Updated: Jun 6, 2026
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy
Sherry W Yang1, James J Cody, Angel A Rivera
1Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0007, USA.
Purpose:
Current treatments for ovarian cancer have limited therapeutic outcomes due to advanced stage of the disease at diagnosis. Among new therapies, conditionally replicating adenoviruses (CRAds), designed to selectively lyse cancer cells, hold promise. In clinical trials, CRAds exhibited limited efficacy thus far. Second-generation CRAds are being developed to express a therapeutic protein to enhance antitumor efficacy. One attractive target in the tumor microenvironment is the matrix metalloproteinases (MMPs) that degrade the extracellular matrix, and are upregulated in ovarian cancer. Tissue inhibitor of metalloproteinase 2 (TIMP2) is an endogenous inhibitor of MMPs. The present study developed and evaluated a novel CRAd (Ad5/3-CXCR4-TIMP2) for ovarian cancer therapy.
Experimental Design:
A targeted CRAd, Ad5/3-CXCR4-TIMP2 was developed using the CXCR4 promoter for enhanced replication, and expressing the TIMP2 transgene. The efficacy of this armed CRAd was determined in both established human ovarian cancer cell lines and in primary ovarian tumor samples.
Results:
Ad5/3-CXCR4-TIMP2 mediated expression of functional TIMP2, as demonstrated by the inhibition of MMP activity. In addition, arming with TIMP2 did not inhibit viral replication or oncolytic potency, as the TIMP2-armed viruses showed enhanced killing of cancer cells when compared to the unarmed viruses. We also examined viral replication in primary ovarian cancer tissues obtained from patients with stage III and IV ovarian cancer. In four of the five tumor samples, Ad5/3-CXCR4-TIMP2 revealed a 21- to 89-fold increase in replication when compared to the Ad5/3 virus.
Conclusion:
Results support the translational potential of Ad5/3-CXCR4-TIMP2 for treatment of patients with advanced ovarian cancer.
Insights
A novel conditionally replicating adenovirus (CRAd) armed with Tissue Inhibitor of Metalloproteinase 2 (TIMP2) shows promise for treating advanced ovarian cancer by enhancing tumor cell killing and viral replication.
Area of Science:
- Oncolytic virotherapy
- Gene therapy for cancer
- Tumor microenvironment modulation
Background:
- Ovarian cancer treatment is limited by late-stage diagnosis.
- Conditionally replicating adenoviruses (CRAds) offer targeted cancer cell lysis.
- Second-generation CRAds aim to improve efficacy by expressing therapeutic proteins.
Purpose of the Study:
- To develop and evaluate a novel CRAd, Ad5/3-CXCR4-TIMP2, for ovarian cancer therapy.
- To enhance antitumor efficacy by targeting matrix metalloproteinases (MMPs) using TIMP2.
Main Methods:
- Developed Ad5/3-CXCR4-TIMP2 using the CXCR4 promoter for replication and expressing the TIMP2 transgene.
- Assessed CRAd efficacy in human ovarian cancer cell lines and primary tumor samples.
- Evaluated TIMP2 expression and its effect on MMP activity.
Main Results:
- Ad5/3-CXCR4-TIMP2 successfully expressed functional TIMP2, inhibiting MMP activity.
- TIMP2-armed CRAd demonstrated enhanced cancer cell killing compared to unarmed CRAd.
- Significant viral replication (21- to 89-fold increase) observed in patient-derived ovarian tumors.
Conclusions:
- Ad5/3-CXCR4-TIMP2 exhibits translational potential for advanced ovarian cancer treatment.
- The TIMP2-armed CRAd enhances oncolytic potency and viral replication in ovarian tumors.
